Clinical Trials Logo

Type 2 Diabetes Mellitus clinical trials

View clinical trials related to Type 2 Diabetes Mellitus.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT03731533 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus

WellStart Reboot Study

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

This is a randomized, controlled comparison study that will evaluate the effectiveness of WellStart, a virtual intensive therapeutic lifestyle change program to control type 2 diabetes.

NCT ID: NCT03437720 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus

Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease

Restore
Start date: May 23, 2019
Phase: Phase 2
Study type: Interventional

Primary Objective: - To evaluate the dose response relationship of SAR425899 compared to placebo on resolution of non-alcoholic steatohepatitis (NASH) with no worsening of fibrosis in diabetic and non-diabetic patients with histopathologically-confirmed NASH. Secondary Objectives: - To assess the effect of SAR425899 on overall non-alcoholic fatty liver disease (NAFLD) activity score (NAS), individual components of NAS (steatosis, hepatocyte ballooning, and lobular inflammation), and fibrosis score. - To assess to the effect of SAR425899 on MRI-PDFF (Magnetic Resonance Imaging-determined Proton Density Fat Fraction) derived parameters (total liver fat, liver volume, and fractional liver fat content). - To assess the effect of SAR425889 on body weight and waist/hip circumference ratio. - To assess SAR425899 pharmacokinetics. - To assess safety and tolerability of SAR425899.

NCT ID: NCT03417076 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus

Absolute Bioavailability Study With Bexagliflozin

Start date: August 1, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.

NCT ID: NCT03121508 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus

Taking on Diabetes to Advance You (TODAY)

TODAY
Start date: April 24, 2017
Phase: N/A
Study type: Interventional

The program will consist of diabetes self-management sessions, led by an occupational therapist. The sessions will be held in an individualized format. Sessions will focus on diabetes education, self-management education, and education on behaviors and adaptive techniques to optimize participation in daily life with type II diabetes. As occupational therapists, the investigators and facilitator, aim to focus on establishing healthy habits, roles, and routines for individuals with type 2 diabetes.

NCT ID: NCT02769091 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus

A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes

NASH
Start date: September 30, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effect of TEV-45478, as compared with placebo, on liver health and liver fat content in patients with T2DM who also have Nonalcoholic Steatohepatitis (NASH).

NCT ID: NCT02694289 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus

Effects of Metformin in Heart Failure Patients

Start date: November 2016
Phase: N/A
Study type: Interventional

Hypothesis: In patients, who have diabetes type 2, are treated with metformin, and are admitted for HF, leads to reduced insulin requirements, as measured in units of insulin, with no negative impact on patient safety. This is a single center, prospective trial. Subjects will be randomized to initiate metformin (starting dose 500mg orally once daily up to a maximum dose of 2,500mg daily) OR be placed on insulin products for management of their type 2 diabetes mellitus.

NCT ID: NCT02579148 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus

Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes

Start date: September 2015
Phase: Phase 1
Study type: Interventional

The intent of this clinical study is to answer the questions: 1) is the proposed treatment feasible; 2) is treatment effective in improving the disease pathology of patients with diagnosed diabetic erectile dysfunction.

NCT ID: NCT02440061 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus

Ghrelin and Beta Cell Function in Diabetes

Start date: May 2018
Phase: Phase 1
Study type: Interventional

Ghrelin is a hormone naturally produced in the stomach and the gut. The purpose of this research study is to determine the role of this gut hormone in the regulation of insulin secretion from the pancreas and glucose disposal after we eat. The investigators hypothesize that ghrelin has an effect on the pancreas and on how our body handles glucose after we eat. The investigators will compare insulin secretion and glucose changes during meal ingestion while either acyl ghrelin (AG) or saline (salt solution) is being infused through your vein on separate study days. AG is a form of the ghrelin hormone that has a small modification to it that allows it to bind to a specific receptor. The investigators hypothesize that AG has an effect on how the body handles glucose after a meal. AG has been approved by the U.S. Food and Drug Administration (FDA) for human research only. This study will also involve the use of a medicine called arginine, which is a naturally occurring product and found in many nutritional supplements. Its use in this study is investigational. The use of arginine helps maximize insulin release from the pancreas so the investigators can better examine whether AG affects insulin secretion.

NCT ID: NCT02310009 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus

IL-1RA, Acute Exercise, and Beta-cell Function

ANEX
Start date: December 2014
Phase: N/A
Study type: Interventional

Subjects (N=48) with poorly-controlled type 2 diabetes (HbA1c>7%) will be assigned to one of the 4 following interventions in a randomised, parallel group design: [I] Control (placebo injection; no exercise), [II] Anakinra (100 mg subcutaneous injection of human recombinant interleukin-1 receptor antagonist), [III] Exercise (1 h cycle ergometry at 75% VO2max), [IV] Anakinra + Exercise. Pancreatic beta-cell function (plasma insulin responses) will be measured before and after each intervention using a hyperglycemic clamp (5.4 mM above basal glucose) combined with GLP-1 infusion (0.5 pmol/kg/min) and arginine injection (5 g bolus).

NCT ID: NCT02250794 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus

Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit

Start date: October 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to test whether a combination of two pills commonly used to treat outpatient diabetes called metformin and sitagliptin (januvia) could provide successful control of blood sugar levels in patients with type 2 diabetes during hospitalization for the treatment of a general medical condition. Both metformin and sitagliptin are currently approved by the Food and Drug Administration for the treatment of type 2 diabetes, but little experience exists for their use in hospitalized patients. The current standard practice is to use insulin injections to control blood sugar in hospitalized patients with type 2 diabetes. This study will compare the use of metformin tablets twice per day along with sitagliptin tablets once per day with daily insulin injections in patients with type 2 diabetes during hospitalization, and will study how well the blood sugar levels are controlled.